Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00002099
Other study ID # 126B
Secondary ID 92-11-9
Status Active, not recruiting
Phase Phase 2
First received November 2, 1999
Last updated June 23, 2005

Study information

Verified date July 1994
Source NIH AIDS Clinical Trials Information Service
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

To determine the tolerance and side effects of a combination of lentinan and didanosine (ddI) in comparison with ddI alone. To determine whether the combination of lentinan and ddI produces a significant immunorestorative effect within the study observation period (6-12 months) as measured by an increase in one or more of the following: neutrophil count and activity, T-cell subsets, and a decrease in p24 antigen.


Description:

Patients are treated with daily oral ddI for 6 weeks, then are randomized to ddI in combination with intravenous lentinan or placebo (administered once weekly) for 26 weeks. Patients who are already stabilized on 400 mg/day ddI will proceed directly to randomization. Following completion of the combination therapy, patients may be offered 26 additional weeks of therapy on an optional basis.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria

Patients must have:

- HIV seropositivity.

- Absolute CD4 count of 200 - 500 cells/mm3.

- No active opportunistic infection or Kaposi's sarcoma.

Prior Medication:

Allowed:

- Prior ddI for no longer than 3 months.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

- Lymphoid malignancy.

- Pancreatitis.

- Peripheral neuropathy.

- Critical illness.

Concurrent Medication:

Excluded:

- Antiretroviral agents other than ddI.

- Steroids.

- Cytotoxic agents.

- Immunosuppressive agents.

- Immunomodulators.

- 1-Thyroxine.

Concurrent Treatment:

Excluded:

- Radiotherapy.

Prior Medication:

Excluded within 1 month prior to study entry:

- Antiretroviral agents other than ddI (patients may have received prior ddI for no longer than 3 months total).

- Steroids.

- Cytotoxic agents.

- Immunosuppressive agents.

- Immunomodulators.

Prior Treatment:

Excluded:

- Radiotherapy within 1 month prior to study entry. Active IV drug abuse.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Lentinan

Didanosine


Locations

Country Name City State
United States HIV Research Group San Diego California

Sponsors (1)

Lead Sponsor Collaborator
AJI Pharma USA

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Recruiting NCT03256435 - PrEP Intervention for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Enrolling by invitation NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2
Recruiting NCT03271307 - Use of HIV Self-Test Kits to Increase Identification of HIV-Infected Individuals and Their Partners N/A
Active, not recruiting NCT01852942 - Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV Phase 2
Active, not recruiting NCT01937455 - A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults. Phase 1
Withdrawn NCT01975012 - Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Active, not recruiting NCT01931358 - Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E Phase 2
Completed NCT01968551 - Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults Phase 3
Completed NCT01923610 - Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B Phase 1
Recruiting NCT01439503 - Safer Sex Program for Young African-American Men Phase 2
Terminated NCT01583439 - The Mochudi Prevention Project ART Protocol N/A
Completed NCT01440569 - Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults Phase 3
Completed NCT01053598 - Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting N/A
Recruiting NCT01204905 - R5 Integrase Study in HIV-1 Naive Patients N/A
Recruiting NCT01428596 - Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects Phase 1
Recruiting NCT01176409 - Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2? Phase 3
Completed NCT00639145 - Elizabeth Glaser Pediatric AIDS Foundation Maternal Events and Pregnancy Outcomes (MEP Project)A Multi-site Protocol N/A
Completed NCT01095224 - Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults Phase 1